Why Doesn’t the NHS Bring Medical Cannabis Prices Down?

Medical cannabis has been a topic of growing interest and debate in the UK. Despite its increasing availability on prescription, patients and healthcare professionals alike often ask: why doesn’t the NHS bring medical cannabis prices down? This question involves several layers, including how medical cannabis is prescribed, the differences between smoking and vaporising, the role of devices, and regulatory frameworks.

Understanding UK Prescribed Cannabis: Vaporisation, Not Smoking

First, it is important to clarify a common misconception. In the UK, prescribed medical cannabis products are vaporised, not smoked. The term “smokable cannabis” is widely used informally but is misleading and inaccurate when discussing NHS prescriptions.

Here’s the key difference:

• Smoking involves combustion — burning the cannabis flower, which produces smoke, tar, and other harmful by-products.
• Vaporising heats the cannabis to a point where cannabinoids evaporate into a vapor without burning the plant material, reducing harmful inhalants.

Medical cannabis prescribed by the NHS is supplied in forms that must be vaporised using a medical device. This significantly reduces health risks associated with combustion by-products like polyaromatic hydrocarbons and carbon monoxide.

Why Vaporisation Matters for Patients

Combustion by-products inhaled from smoking cannabis can irritate lungs and increase long-term respiratory risks. Vaporisation is a cleaner method that delivers cannabinoids efficiently and with better dose control. In the context of the NHS and regulated prescribing, vaporisation is preferred for safety and consistent dosing concerns.

The Device is Part of Treatment: More Than Just Medicine

Unlike many standard oral medicines, prescribed medical cannabis requires a specific delivery device to be used properly. This device is pivotal — it ensures accurate dosing and a safe, consistent inhalation experience for the patient.

The cost of these devices is not negligible:

Device Type Purpose Typical Cost Range Vaporiser Pen (Medical Grade) Vaporising cannabis oil or dried flower £150 - £300 Replacement Parts (Batteries, Chambers) Device maintenance £20 - £50 per set

Because the device is integral to treatment, costs for prescribed medical cannabis should include both the product and the device. This adds complexity to NHS supply and pricing considerations.

Limited NHS Prescribing: The Core Reason for High Prices

The biggest driver behind the relatively high cost of NHS medical cannabis is limited NHS prescribing. Here’s what’s happening:

1. Currently, very few patients in the UK receive medical cannabis on an NHS prescription.
2. Prescribing is restricted to specialist clinicians after other treatment options have been tried.
3. This leads to very small volume orders through the NHS system.
Look at more info

Unlike medicines prescribed widely in the NHS, medical cannabis does not benefit from economies of scale in purchasing. Large-volume NHS contracts for common medicines bring prices down; this does not happen for medical cannabis because few patients and clinics are involved.

No Large Public Purchaser for Medical Cannabis

The NHS is one of the world’s largest single medicine purchasers. However:

• Medical cannabis products cannot be bought in bulk at scale through NHS England or NHS supply chains because of limited approved indications and prescribing guidelines.
• Pharmaceutical companies and suppliers face very small NHS demand, so wholesale price discounts and supply agreements typical of common medicines are absent.
• The existing private medical cannabis market, which is significantly larger than NHS prescribing, operates at prices driven by the supplier-patient relationship outside NHS bulk purchasing mechanisms.

In essence, the NHS does not have the purchasing power for medical cannabis that it has for established medicines like insulin or statins.

Pharmacy and GPhC Regulation Adds Another Layer

Dispensing medical cannabis in the UK is highly regulated to ensure patient safety:

• Pharmacies must be registered with the General Pharmaceutical Council (GPhC).
• Medical cannabis is a controlled drug, requiring strict storage, record-keeping, and handling protocols.
• Pharmacists must have specialist training on these products and devices.

These regulatory requirements generate additional operating costs for pharmacies, which influence the final cost passed on to the NHS or patient.

vaping cannabis flower safely

Unlike most common prescription medicines, medical cannabis products and their associated devices require more careful handling, which limits wholesale or discount opportunities.

Breaking Down the Cost: Private Market vs NHS Pricing

It is often claimed that medical cannabis is cheaper privately than on the NHS. To understand why, let's look at a cost breakdown:

Cost Element NHS Setting Private Setting Medicine price per month £500 - £700 (low volume supply) £350 - £600 (market-driven prices) Device cost (amortized monthly) £15 - £25 Included or patient-buys Pharmacy handling fees Higher (controlled drug protocols) Variable (private clinics sometimes bundle costs) Consultation and specialist fees Covered by NHS (limited) £150 - £300 per visit

In private clinics, although the medicine price itself may appear lower, patients pay consultation fees and often purchase their device separately. The apparent difference in medicine cost partly reflects scale, competition, and different pricing strategies.

Why Bulk Purchasing Could Lower Prices—But Isn’t Happening Yet

Bulk purchasing powers below-the-line medicine costs down by:

• Enabling NHS England to negotiate direct procurement with manufacturers at discounted rates.
• Encouraging suppliers to commit to long-term contracts with reliable demand.
• Lowering pharmacy handling and distribution costs through centralised supply chains.

However, for medical cannabis, this is still a distant reality because:

1. Clinical evidence and NHS guidelines remain cautious, limiting large-scale prescribing.
2. No established NHS commissioning framework for large-volume buying exists.
3. Supplier market and prescribing patterns remain fragmented between private and NHS sectors.

Summary: Why NHS Medical Cannabis Prices Stay High

• Medical cannabis is vaporised, not smoked, requiring specialist devices that add cost.
• Limited NHS prescribing volumes mean no sizeable public purchasing agreements.
• Private market pricing operates differently, with patient-pay models outside NHS bulk discounts.
• Pharmacy and GPhC regulations add complexity and cost to dispensing controlled cannabis products.
• No centralized NHS procurement framework yet exists to leverage the NHS’s usual bulk purchasing advantages.

Until NHS prescribing broadly expands and procurement frameworks develop, medical cannabis prices on the NHS are unlikely to come down substantially. Patients and clinicians alike must navigate these realities while advocating for more research, clearer prescribing guidance, and fairer pricing models.